Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis

Afzal KI, Anam S, Hunter SJ (2017) The effects of antiepileptic drugs on pediatric cognition, mood, and behavior. J Pediatr Epilepsy 6:3–18. https://doi.org/10.1055/s-0036-1584935 Allison M (2012) Reinventing clinical trials. Nature Biotechnol 30:41–49. https://doi.org/10.1038/nbt.2083 Alvarez MdL et al (2002) The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology 35:824–833. https://doi.org/10.1053/jhep.2002.32099 Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nature Neurosci 6:51–58. https://doi.org/10.1038/nn992 Andronis C, Sharma A, Deftereos S, Virvilis V, Konstanti O, Persidis A, Persidis A (2012) Mining Scientific and Clinical Databases to Identify Novel Uses for Existing Drugs. In: Drug Repositioning. John Wiley & Sons, Ltd, pp 137–161. https://doi.org/10.1002/9781118274408.ch6 Bal-Price A, Meek ME (2017) Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity. Pharmacol Therapeut 179:84–95. https://doi.org/10.1016/j.pharmthera.2017.05.006 Bal-Price A, Crofton KM, Sachana M, Shafer TJ, Behl M, Forsby A et al (2015) Putative adverse outcome pathways relevant to neurotoxicity. Crit Rev Toxicol 45:83–91. https://doi.org/10.3109/10408444.2014.981331 Bal-Price A, Lein PJ, Keil KP, Sethi S, Shafer T, Barenys M et al (2017) Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. Neurotoxicol 59:240–255. https://doi.org/10.1016/j.neuro.2016.05.010 Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH (2016) A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data 3:160026–160026. https://doi.org/10.1038/sdata.2016.26 Adverse Outcome Pathway Knowledge Base (AOP-KB). Available at: https://aopkb.oecd.org/index.html. Accessed on 11/2019 Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427–436. https://doi.org/10.1002/pds.1742 Bauer B, Hartz AMS, Fricker G, Miller DS (2005) Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 230:118–127. https://doi.org/10.1177/153537020523000206 Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH (2007) Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacol 32:1888–1902. https://doi.org/10.1038/sj.npp.1301312 Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB (2019) An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the european medicines agency. Expert Opin Drug Saf 18:1055–1063. https://doi.org/10.1080/14740338.2019.1665022 Bhattacharya S et al (2018) ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data 5:180015. https://doi.org/10.1038/sdata.2018.15 Bodenreider O (2004) The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 32:D267–D270. https://doi.org/10.1093/nar/gkh061 Breuer K et al (2013) InnateDB: systems biology of innate immunity and beyond–recent updates and continuing curation. Nucleic Acids Res 41:D1228–D1233. https://doi.org/10.1093/nar/gks1147 Brombacher TM et al (2017) IL-13–mediated regulation of learning and memory. J Immunol 198:2681–2688. https://doi.org/10.4049/jimmunol.1601546 Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226–238. https://doi.org/10.1016/j.pharmthera.2011.01.014 Caster O, Juhlin K, Watson S, Norén GN (2014) Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf 37:617–628. https://doi.org/10.1007/s40264-014-0204-5 Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Rev Drug Discov 13:419–431. https://doi.org/10.1038/nrd4309 Cotto KC et al (2018) DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res 46:D1068–D1073. https://doi.org/10.1093/nar/gkx1143 Crowther M (2013) Phase 4 research: what happens when the rubber meets the road? Hematol Am Soc Hematol Educ Program 2013:15–18. https://doi.org/10.1182/asheducation-2013.1.15 Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A (2011) Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip Rev Syst Biol Med 3:323–334. https://doi.org/10.1002/wsbm.147 Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, Kipnis J (2010) Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med 207:1067–1080. https://doi.org/10.1084/jem.20091419 Duggirala H et al. (2018) Data Mining at FDA - Data Mining at FDA - White Paper Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259. https://doi.org/10.1016/S0140-6736(00)02799-9 Erickson MA, Banks WA (2018) Neuroimmune axes of the blood–brain barriers and blood–brain interfaces: Bases for physiological regulation, disease states, and pharmacological interventions. Pharmacol Rev 70:278–314. https://doi.org/10.1124/pr.117.014647 Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483–486. https://doi.org/10.1002/pds.677 Food and Drug Administration (FDA) (2018) Questions and Answers on FDA's Adverse Event Reporting System (FAERS). https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed on 11/2019 Fragoso YD et al (2010) Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol 33:312–316. https://doi.org/10.1097/WNF.0b013e3181f8d513 Goji H, Kanemoto K (2019) The effect of perampanel on aggression and depression in patients with epilepsy: A short-term prospective study. Seizure 67:1–4. https://doi.org/10.1016/j.seizure.2019.02.009 Gupta A, Chadda RK (2016) Adverse psychiatric effects of non-psychotropic medications. BJPsych Adv 22:325–334. https://doi.org/10.1192/apt.bp.115.015735 Hartz AMS, Bauer B, Fricker G, Miller DS (2006) Rapid modulation of p-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-α and lipopolysaccharide. Mol Pharmacol 69:462–470. https://doi.org/10.1124/mol.105.017954 Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316. https://doi.org/10.1016/j.biopsych.2007.03.017 Kaminska B (2005) MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754:253–262. https://doi.org/10.1016/j.bbapap.2005.08.017 Labonte B, Turecki G (2012) Epigenetic effects of childhood adversity in the brain and suicide risk. In: The neurobiological basis of suicide. 2012. Dwivedi Y (ed): Boca Raton (FL, USA) Lindquist M (2008) VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J 42:409–419. https://doi.org/10.1177/009286150804200501 Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RH (2000) A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 23:533–542. https://doi.org/10.2165/00002018-200023060-00004 Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J (2017) Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest 127:3210–3219. https://doi.org/10.1172/JCI90603 Lutz SE et al (2017) Caveolin Is Required for Th1 Cell Infiltration, but Not Tight Junction Remodeling, at the Blood-Brain Barrier in Autoimmune Neuroinflammation. Cell Rep 21:2104–2117. https://doi.org/10.1016/j.celrep.2017.10.094 Maciejewski M, Lounkine E, Whitebread S, Farmer P, DuMouchel W, Shoichet BK, Urban L (2017) Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. Elife 6:e25818. https://doi.org/10.7554/eLife.25818 Maeng S, Zarate CA Jr (2007) The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 9:467–474. https://doi.org/10.1007/s11920-007-0063-1 Martucci L, Wong AH, De Luca V, Likhodi O, Wong GW, King N, Kennedy JL (2006) N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res 84:214–221. https://doi.org/10.1016/j.schres.2006.02.001 Meador-Woodruff JH, Hogg AJ Jr, Smith RE (2001) Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 55:631–640. https://doi.org/10.1016/s0361-9230(01)00523-8 Merico D, Isserlin R, Stueker O, Emili A, Bader GD (2010) Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 5:e13984–e13984. https://doi.org/10.1371/journal.pone.0013984 Misiak B, Beszłej JA, Kotowicz K, Szewczuk-Bogusławska M, Samochowiec J, Kucharska-Mazur J, Frydecka D (2018) Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Progr Neuro-Psychopharmacol Biol Psychiatry 80:177–188. https://doi.org/10.1016/j.pnpbp.2017.04.021 Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905–908. https://doi.org/10.1111/j.1365-2125.2011.04037.x Muderrisoglu AE, Becher KF, Madersbacher S, Michel MC (2019) Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf 18:915–923. https://doi.org/10.1080/14740338.2019.1652269 Nerurkar L, Siebert S, McInnes IB, Cavanagh J (2019) Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6:164–173. https://doi.org/10.1016/S2215-0366(18)30255-4 Pan W, Kastin AJ (2002) TNFα transport across the blood–brain barrier is abolished in receptor knockout mice. Exp Neurol 174:193–200. https://doi.org/10.1006/exnr.2002.7871 Pan W, Banks WA, Kastin AJ (1997) Permeability of the blood-brain and blood-spinal cord barriers to interferons. J Neuroimmunol 76:105–111. https://doi.org/10.1016/S0165-5728(97)00034-9 Patel A, Zhu Y, Kuzhikandathil EV, Banks WA, Siegel A, Zalcman SS (2012) Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS ONE 7:e41623. https://doi.org/10.1371/journal.pone.0041623 Adverse Outcome Pathway -Wiki (AOP-Wiki). Available at: https://aopwiki.org. Accessed on 11/2019 Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS (2015) Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacol 96:235–243. https://doi.org/10.1016/j.neuropharm.2014.12.028 Pletz J et al (2018) A critical review of adverse effects to the kidney: mechanisms, data sources, and in silico tools to assist prediction. Expert Opin Drug Metab Toxicol 14:1225–1253. https://doi.org/10.1080/17425255.2018.1539076 Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H (2010) Regulation of bcrp (ABCG2) and p-glycoprotein (ABCB1) by cytokines in a model of the human blood–brain barrier. Cell Mol Neurobiol 30:63–70. https://doi.org/10.1007/s10571-009-9431-1 Poluzzi E, Raschi E, Piccinni C, De Ponti F (2012) Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS) N2 - data mining applications in engineering and medicine targets to help data miners who wish to apply different data mining techniques. 2012. Karahoca, E (ed): IntechOpen CY, Rijeka. https://doi.org/10.5772/50095 Postigo R et al (2018) Eudravigilance medicines safety database: Publicly accessible data for research and public health protection. Drug Saf 41:665–675. https://doi.org/10.1007/s40264-018-0647-1 Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J (2019) g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res 47:W191–W198. https://doi.org/10.1093/nar/gkz369 Renault PF et al (1987) Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147:1577–1580 Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10:796–803. https://doi.org/10.7150/ijms.6048 Samanen J (2013) Chapter 5 - Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. In: Ganellin R, Roberts S, Jefferis R (eds) Introduction to Biological and Small Molecule Drug Research and Development. Elsevier, Oxford, pp 161–203. https://doi.org/10.1016/B978-0-12-397176-0.00005-4 Scarr E (2009) Muscarinic Receptors in Psychiatric Disorders – Can We Mimic ‘Health’? Neurosignals 17:298–310. https://doi.org/10.1159/000231896 Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B (2003) Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 5:257–264. https://doi.org/10.1034/j.1399-5618.2003.00024.x Sequeira A et al (2009) Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 4:e6585. https://doi.org/10.1371/journal.pone.0006585 Sessa B, Higbed L, Nutt D (2019) A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Front Psychiatry. https://doi.org/10.3389/fpsyt.2019.00138 Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525–535. https://doi.org/10.1038/sj.mp.4001035 Skovlund CW, Mørch LS, Kessing LV, Lange T, Lidegaard Ø (2018) Association of hormonal contraception with suicide attempts and suicides. Am J Psychiatry 175:336–342. https://doi.org/10.1176/appi.ajp.2017.17060616 Stephens SH et al (2009) Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophr Res 109:102–112. https://doi.org/10.1016/j.schres.2008.12.017 Tang YP, Wang H, Feng R, Kyin M, Tsien JZ (2001) Differential effects of enrichment on learning and memory function in NR2B transgenic mice. Neuropharmacol 41:779–790. https://doi.org/10.1016/s0028-3908(01)00122-8 Tsai S-J, Hong C-J, Liou Y-J (2011) Recent molecular genetic studies and methodological issues in suicide research. Progr Neuro-Psychopharmacol Biol Psychiatry 35:809–817. https://doi.org/10.1016/j.pnpbp.2010.10.014 Utge S et al (2010) A population-based association study of candidate genes for depression and sleep disturbance. Am J Med Genet B Neuropsychiatr Genet 153:468–476. https://doi.org/10.1002/ajmg.b.31002 Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998) Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25:39–47 Wick A et al (2004) Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 91:1067–1074. https://doi.org/10.1111/j.1471-4159.2004.02774.x Witkin JM, Marek GJ, Johnson BG, Schoepp DD (2007) Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 6:87–100. https://doi.org/10.2174/187152707780363302 Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G (2010) Glutamatergic modulators: The future of treating mood disorders? Harv Rev Psychiatry 18:293–303. https://doi.org/10.3109/10673229.2010.511059 Zhang C et al (2014) A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacol 231:685–693. https://doi.org/10.1007/s00213-013-3297-0 Zink RC, Huang Q, Zhang L-Y, Bao W-J (2013) Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Chin J Nat Med 11:314–320. https://doi.org/10.1016/S1875-5364(13)60035-7